Navigation Links
PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
Date:4/23/2008

ne 30, 2008), for Fiscal Year 2008, and for Calendar Year 2008, using recent exchange rates. For the fourth quarter, the Company anticipates reporting consolidated service revenue in the range of $255 to $265 million and earnings per diluted share in the range of $0.25 to $0.26. For Fiscal Year 2008, consolidated service revenue is expected to be in the range of $947 to $957 million and earnings per diluted share are projected to be in the range of $0.94 to $0.96. (Previously issued guidance for Fiscal Year 2008 included service revenue of between $935 and $955 million and earnings per diluted share of $0.89 to $0.92). For Calendar Year 2008, expectations are for consolidated service revenue to be in the range of $1.02 to $1.05 billion, and earnings per diluted share to be in the range of $0.98 to $1.02. (Previously issued Calendar Year 2008 guidance projected service revenue of $1.0 billion to $1.04 billion and earnings per diluted share in the range of $0.92 to $0.97).

The Company believes that presenting the proforma information contained in this press release assists investors and others in gaining a better understanding of its core operating results and future prospects, especially when comparing such results to previous periods or forecasted guidance. Management uses this proforma information, in addition to the GAAP information, as the basis for measuring the Company's core operating performance and comparing such performance to that of prior periods and to the performance of its competitors. Such measures are also used by management in its financial and operating decision-making. Proforma information is not meant to be considered superior to or a substitute for the Company's results of operations prepared in accordance with GAAP.

A conference call to discuss PAREXEL's third quarter earnings, business, and financial outlook will begin at 10:00 a.m. ET on Thursday, April 24th and will be broadcast live over the internet via webcast. The webcast m
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...stCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglob...dthatithassubmittedaMAAtotheEuropeanMedicinesAgenc...nttherapyindevelopment,forthetreatmentofType1Gauch...laglucerasealfathathasbeensubmitted,withprevious,s...onaglobalsupplyshortageofthecurrentlyapprovedandma...
(Date:11/24/2009)...e/--HealthRoboticstodayannounced,thatithasformedan...rs.ThisrecentlyformedToronto-basedcompanywillopera...ket,install,andsupport,HealthRobotics,i.v.Roomofth...ctofferingsi.v.STATION(TM),i.v.SOFT(TM),andOMM(TM)...eonan"asneeded,basis"toitsstrategicpartnershipswit...
(Date:11/24/2009)...all/--CellTherapeutics,Inc.(CTI)(NasdaqandMTA:CTIC...ealthCareConference.TheconferencewillbeheldDecembe...esentonTuesday,December1at11:00a.m.EasternTimeinHo...onwillbeavailableat www.celltherapeutics.com ,andi...JaffrayHealthCareConference,NewYorkPalaceHotel,Hol...
(Date:11/23/2009)...communication, computation and more powerful ways ...e quantum states as carriers of information is an ...ve shown, mathematically, how to gently tease out ...ping the information intact. Their work is reporte... and highlighted with a Viewpoint in Physics ( ...
Breaking Biology Technology:Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...ical Animal Data Demonstrates Selective Survival A...after HIV Infection, RICHMOND, Calif., Sept. 18 /...(Nasdaq: SGMO ) announced today the presentation ...e made permanently resistant to,HIV infection by t...eases,(ZFN(TM)) and preferentially survive and exp...
...rings The New Face of Research - the New ISI Web o...nstitutions Throughout the Country, PHILADELPHIA ...The Thomson Corporation (NYSE: TOC ; TSX: TOC) an... worldwide research and,business communities, anno...a la Ciencia y la Tecnologia (FECYT) has renewed i...
...H TRIANGLE PARK, N.C., Sept. 18 ,Siemens Medical S...d Xintek Inc.,announce today that they have signed... in Research Triangle Park, N.C. The mission of th... a new multi-pixel X-ray source,technology for a b...ogo: http://www.newscom.com/cgi-bin/prnh/20070904...
Other Biology Technology:Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 2Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 4Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 5Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 2Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 3Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes 2
(Date:11/23/2009)...r 23, 2009 - The time of day matters to forest tre...produced by a research team led by Professor Malco...ice-principal for research and colleagues in the d...eorge campus. , Capitalizing on their previous... research team examined how poplar trees use their...
(Date:11/23/2009)... only swine vaccine available for the H1N1 virus h...th the virus. The vaccination marks the first time...ith the pandemic flu., Iowa State University,s H... the vaccine this summer and has been shipping pre...nd Illinois for several weeks., The latest vacci...
(Date:11/23/2009)...wo new studies reveal in unprecedented detail how ...emble new proteins and guide them toward their des...ecular dynamics flexible fitting (MDFF) to examine...t molecular partners. , The first study, in Pr...ncerns the intimate signaling between the ribosome...
Breaking Biology News(10 mins):Time of day matters to thirsty trees, U of T researcher discovers 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3COSHAR Foundation Promotes Importance of Timely Childhood Immunization at Black Family Reunion Celebration in Washington D C 56444 1COSHAR Foundation Promotes Importance of Timely Childhood Immunization at Black Family Reunion Celebration in Washington D C 56444 2BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 4954 1BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 4954 24 Balzan 2009 prize winners announced in Milan 56438 14 Balzan 2009 prize winners announced in Milan 56438 2
...rability during ePassports EAC Conform...ept. 9 After successful deployment,of their first...gain has,selected Entrust, Inc. (Nasdaq: ENTU ) t...ond-generation ePassport solution based on the Ext...ovenia becomes one of the first,countries in the w...
...so-called triglycerides in specialized fatty tissu...he delicate balance of the lipid metabolism gets o... leading to the dreaded fatty liver. This increase... metabolic syndrome known as "deadly quartet". Thi...d hypertension is regarded as the primary cause of...
... France,s presidency of the EU, Lille will play ho...e GMES (Global Monitoring for Environment and Secu...s relating to the environment, climate change, res...e services draw on data - mainly Earth observation...combined with socio-economic data, processed in su...
Other Biology News:Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 2Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 3Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 4Entrust Expands Relationship with Slovenia, Implements Second-generation ePassport Solution 5Cortisol and fatty liver: Researchers find cause of severe metabolic disorders 2Major European program for the environment under the spotlight in Lille, France 2
Human Complement C1r from BIOPUR
...on Designer designs oligos for SYBR Green, TaqMan,...NASBA and FRET assays. Highly specific primers are...tomatically interpreting BLAST search results. Pri...condary structures identified by connecting to the...
...ists of the LVF-HL, LVF-CUVADPT, FHS-LVF, and the ... and low-pass Linear Variable Filters to create th...nter wavelength and adjustable bandpass. Each filt...and blocking band (99.8%). These filters -- with ...
Custom siRNA, HPLC purified, annealed from Ambion
Biology Products: